Look up one drug

Reason for Use code 550 For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria: (i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C. (ii) Laboratory confirmed hepatitis C genotype 1, 2, 3, 4, 5, or 6; (iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart; OR One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). Exclusion criteria: - Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor - For use in combination with other hepatitis C antiviral agents - Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C) Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program. Treatment regimens for Maviret: I. Treatment-naive, non-cirrhotic genotype 1, 2, 3, 4, 5, or 6. Approved duration: 8 weeks II. Treatment-naive genotype 1, 2, 3, 4, 5, or 6 with compensated cirrhosis. Approved duration: 8 weeks III. Treatment-experienced, non-cirrhotic genotype 1, 2, 4, 5, or 6 who have failed peginterferon/ribavirin and/or sofosbuvir ONLY. Approved duration: 8 weeks Notes: (1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations. (2) NS3/4A Pls include simeprevir, boceprevir, and telepravir. (3) NS5A inhibitors include daclatasvir and ledipasvir. Coverage limit: LU Authorization Period: 8 Weeks Reason for Use code 551 For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria: (i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; (ii) Laboratory confirmed hepatitis C genotype 1, 2, 4, 5, or 6; (iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart; OR One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). Exclusion criteria: - Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor - For use in combination with other hepatitis C antiviral agents - Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C) Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program. Treatment regimens for Maviret: I. Treatment-experienced, genotype 1, 2, 4, 5, or 6 with compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY. Approved duration: 12 weeks II. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS3/4A protease inhibitor (2) but are NS5A inhibitor naive. Approved duration: 12 weeks Notes: (1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations. (2) NS3/4A PIs include simeprevir, boceprevir, and telepravir. (3) NS5A inhibitors include daclatasvir and ledipasvir. Coverage limit: LU Authorization Period: 12 Weeks. Reason for Use code 552 For treatment-naive or treatment-experienced (1) adult patients with chronic hepatitis C (CHC) infection who meet all the following criteria: (i) Treatment is prescribed by a hepatologist, gastroenterologist, infectious disease specialist or other prescriber experienced in treating chronic hepatitis C; (ii) Laboratory confirmed hepatitis C genotype 1 or 3; (iii) Established chronicity of HCV infection either by two laboratory confirmed quantitative HCV RNA values taken at least 6 months apart; OR One recent laboratory confirmed quantitative HCV RNA within the past 6 months and clinical features establishing a duration of HCV infection longer than 6 months (e.g. presence of fibrosis, presence of non-liver manifestations of HCV, prolonged ALT elevation greater than 6 months without another cause, HCV antibody positivity greater than 6 months), or risk factors for HCV acquisition greater than 6 months (e.g. injection drug use). Exclusion criteria: - Patients with genotype 1 who have relapsed but are treatment experienced on both an NS3/4A protease inhibitor and an NS5A inhibitor - For use in combination with other hepatitis C antiviral agents - Patients with decompensated cirrhosis or severe hepatic impairment (Child-Pugh C) Retreatment is not funded. Retreatment for re-infection in patients who have received an adequate prior course of Maviret will be considered on a case-by-case basis through the Exceptional Access Program. Treatment regimens for Maviret: I. Treatment-experienced genotype 1 non-cirrhotic or compensated cirrhosis who have failed an NS5A inhibitor (3) but is NS3/4A protease inhibitor naive. Approved duration: 16 weeks II. Treatment-experienced genotype 3 non-cirrhotic or compensated cirrhosis who have failed peginterferon/ribavirin and/or sofosbuvir ONLY. Approved duration: 16 weeks Notes: (1) Treatment-experienced definitions vary by the genotype being treated. Health care professionals are advised to refer to the Maviret product monograph and prescribing guidelines for appropriate use of the drug product, including use in special populations. (2) NS3/4A PIs include simeprevir, boceprevir, and telepravir. (3) NS5A inhibitors include daclatasvir and ledipasvir. Coverage limit: LU Authorization Period: 16 Weeks.

Maviret · DIN 02467550 Manufacturer: AbbVie Corporation; listing date 2019-02-28 Health Canada: Marketed since 2017-09-13 · brand MAVIRET · ATC J05AP57 GLECAPREVIR AND PIBRENTASVIR, J05AP57 GLECAPREVIR AND PIBRENTASVIR · form Tablet · route Oral · ingredients PIBRENTASVIR 40 MG, GLECAPREVIR 100 MG · company Abbvie corporation · schedule Prescription

DIN 02467550: Maviret Raw flags: sec12=Y, sec3=Y Item: 081800391; group id 91; item number 0162; lccId 00314; manufacturer id ABV Source form: Tab; strength: 100mg & 40mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $238.0952; ministry $238.0952 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02467550 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95591

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02467550

Shortage record checked 2026-09-13T08:10:21.292534+00:00